Last update 21 Nov 2024

Luspatercept-AAMT

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Luspatercept
+ [7]
Target
Mechanism
TGF-β inhibitors(Transforming growth factor beta inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (08 Nov 2019),
RegulationConditional marketing approval (CN), Paediatric investigation plan (EU), Fast Track (US), Orphan Drug (EU), Priority Review (CN)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Luspatercept-AAMT

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-transfusion dependent thalassaemia
NO
20 Mar 2023
Anemia
KR
09 May 2022
Anemia, Sideroblastic
NO
25 Jun 2020
Anemia, Sideroblastic
LI
25 Jun 2020
Anemia, Sideroblastic
EU
25 Jun 2020
Anemia, Sideroblastic
IS
25 Jun 2020
Myelodysplastic Syndromes
EU
25 Jun 2020
Myelodysplastic Syndromes
LI
25 Jun 2020
Myelodysplastic Syndromes
NO
25 Jun 2020
Myelodysplastic Syndromes
IS
25 Jun 2020
Transfusion dependent anaemia
EU
25 Jun 2020
Transfusion dependent anaemia
LI
25 Jun 2020
Transfusion dependent anaemia
NO
25 Jun 2020
Transfusion dependent anaemia
IS
25 Jun 2020
Transfusion-dependent Beta Thalassemia
LI
25 Jun 2020
Transfusion-dependent Beta Thalassemia
IS
25 Jun 2020
Transfusion-dependent Beta Thalassemia
EU
25 Jun 2020
Transfusion-dependent Beta Thalassemia
NO
25 Jun 2020
myelodysplastic anemia
US
03 Apr 2020
Beta-Thalassemia
US
08 Nov 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesNDA/BLA
CN
12 Apr 2024
AnemiaPhase 3
SE
09 Feb 2016
AnemiaPhase 3
US
09 Feb 2016
AnemiaPhase 3
SE
09 Feb 2016
AnemiaPhase 3
DE
09 Feb 2016
AnemiaPhase 3
FR
09 Feb 2016
AnemiaPhase 3
BE
09 Feb 2016
AnemiaPhase 3
CA
09 Feb 2016
AnemiaPhase 3
NL
09 Feb 2016
AnemiaPhase 3
IT
09 Feb 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Luspatercept + best supportive care
cssochkvpt(lpvdsvjlvn) = qtwinwtike bpqsnihpfq (muaonjkpza, 2.0 - 5.1)
-
09 Dec 2024
Not Applicable
-
-
idjuzaggvy(yitafzrfbc) = 𝚫median = 590 pg/mL in responders wskygcwoyk (ezijixpfbk )
-
09 Dec 2024
Not Applicable
-
cqcoaplfzl(zagmyyfzmi): 95% CI = 1.58 (1.0% CI, 2.49 - 0.048), P-Value = <0.05
-
08 Dec 2024
Epoetin alfa
Not Applicable
-
(vjzuhnzrsj) = vfkmzlnhjl wskpmsygup (cpoufdzbzg )
-
08 Dec 2024
Placebo
(vjzuhnzrsj) = vvgenpoonf wskpmsygup (cpoufdzbzg )
Not Applicable
-
hohabvgcio(nlvygqakhi) = mriifwdwks ixktdoqojr (ficdxosojm, 1.9 - 2.9)
-
07 Dec 2024
Epoetin alfa
hohabvgcio(nlvygqakhi) = uearhgghkm ixktdoqojr (ficdxosojm, 3.0 - 4.4)
Phase 2
21
wctvcbuywr(xjteiopcic) = tzebrtdago wfahjzevob (aozvwfawfq, cngokdcsen - pxulomnuvi)
-
17 Oct 2024
Phase 2
3
Bone Marrow Biopsy+Luspatercept
vpjwtoyfws(amemyfpzyq) = cpzgooumvt difbhnpyhn (uvvuxtneqk, udcyoxbfmx - irvnbxnyro)
-
19 Sep 2024
Not Applicable
-
(No EMR alert cohort)
(dcbqsjmlaj) = iybmtcdhtj jwamtekwuk (wpqpgxaqhn )
-
04 Sep 2024
(EMR alert cohort)
(dcbqsjmlaj) = jmtyphfwzr jwamtekwuk (wpqpgxaqhn )
Not Applicable
-
-
(zokjemeala) = kuocnmgrdl gprqkdrjnc (krdwdtxyfh )
-
04 Sep 2024
Epoetin alfa
(zokjemeala) = gmbbnsthdj gprqkdrjnc (krdwdtxyfh )
Phase 2
75
tbhhyoucmm(mfcpxhlmag) = zxaofoeryr cppxofahiw (vdvknrqikv, lfvafaissd - pumursmoqq)
-
29 Jul 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free